Compare Krispy Kreme Inc (DNUT) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Krispy Kreme Inc vs Revvity Inc — how do they compare? Krispy Kreme Inc trades at $3.1 (market cap $537.85M), while Revvity Inc trades at $115.25 (market cap $12.91B). The key difference: Revvity Inc is far larger — about 24× Krispy Kreme Inc's market cap, and Krispy Kreme Inc pays the higher dividend (3.47%). Which is the better fit depends on your goals.
| DNUT | RVTY | |
|---|---|---|
Market Cap | $537.85M | $12.91B |
Sector | Consumer Staples | Technology |
52-Week High | $4.70 | $117.75 |
52-Week Low | $2.92 | $82.26 |
Enterprise Value | $1.78B | $15.23B |
Dividend Yield | 3.47% | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Krispy Kreme (DNUT) trades at $3.14, down 5.99% with bearish technical signals. The company shows mixed fundamentals with a high P/E ratio of 216.5 but attractive P/S of 0.36 and P/B of 0.87. Recent Q2 2026 earnings showed a narrowed loss of $0.03 per share, beating expectations, while revenue declined 12.8% due to refranchising. CEO Josh Charlesworth emphasized turnaround progress with margin improvement and deleveraging (Bloomberg, August 6, 2026).
The outlook remains challenging with negative net income margins and ROE, though analyst sentiment is cautiously optimistic with 50% buy ratings. Key risks include execution of the turnaround strategy and competitive pressures. The stock presents a speculative opportunity if management can sustain operational improvements and return to profitability.
RVTY trades at $115.18, down 0.72% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $1.41 per share, beating estimates, and raised its full-year outlook, driven by diagnostics strength and AI-enabled drug discovery. Revenue for 2025 was $2.86 billion with a net income margin of 8.16%, though valuation ratios like P/E of 55.64 appear elevated. Recent news includes product launches like the SuperFlex prenatal system and presentations at investor conferences.
The outlook is positive with analyst consensus favoring a buy rating and a $120.50 price target, suggesting upside. Key opportunities include robust diagnostics demand and innovation pipelines, while risks involve high valuation multiples and competitive pressures in the healthcare sector. Cash flow improved in 2026 to a net positive $31 million, supporting growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Krispy Kreme Inc
Krispy Kreme Inc is a sweet treat brands company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in- your-mouth experience. It operates in 30 countries through its network of fresh Doughnut Shops, partnerships with retailers, and a growing ecommerce and delivery business. The company conducts its business through the following three reported segments namely U.S. and Canada, includes all operations in the U.S. and Canada, Insomnia Cookies shops, and the Branded Sweet Treat Line
Read more on DNUT →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
